3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
7
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neoplasms
1
Neoplasm Metastasis
1
Meningioma
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Glioma
1
Exanthema
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diarrhea
1
Interventions
Rituximab
78
Cyclophosphamide
76
fludarabine phosphate
45
Peripheral Blood Stem Cell Transplantation
41
Mycophenolic Acid
39
Tacrolimus
35
Whole-Body Irradiation
33
Radiotherapy
29
Busulfan
29
Cyclosporine
27
Antilymphocyte Serum
27
Etoposide
25
Filgrastim
24
Methotrexate
22
Melphalan
22
Lenalidomide
15
Cytarabine
15
Cord Blood Stem Cell Transplantation
14
fludarabine
13
Methylprednisolone
13
Bortezomib
13
orelabrutinib
12
Dexamethasone
12
sargramostim
11
obinutuzumab
11
Sirolimus
9
Carmustine
9
zanubrutinib
8
venetoclax
8
Vincristine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, B-Cell, Marginal Zone
×
capivasertib
×
Clear all
NCT05008055
2024-12-20
CAPITAL
AstraZeneca
Phase 2
Completed
30 enrolled
15 charts